Navigation Links
Oral COTI-2 is effective in a second animal model of human pancreatic cancer
Date:1/20/2010

ul>

"In 2010 pancreatic cancer remains the most lethal cancer and effective oral treatments with low toxicity are urgently needed. The results of this second set of experiments confirm that chronically administered oral COTI-2 is a well tolerated effective single agent and there is enhanced efficacy in combination with Abraxane in an animal model of human pancreatic cancer," said Dr. Wayne Danter, President and CSO of COTI. "These results extend previous findings for oral COTI-2 alone and in combination with gemcitabine in pancreatic cancer. We continue to add to the impressive data set for COTI-2, showing effectiveness and low toxicity, particularly in combination with first and second line agents, against multiple cancers."

COTI will present this new data to prospective partners at BioPartnering North America taking place January 24-26, 2010 in Vancouver, Canada. "We are once again delighted with these new experimental results providing further evidence supporting the commercial potential of oral COTI-2 in pancreatic cancer," said Mr. Michael Cloutier, CEO of COTI. "This new data will stimulate further discussions as we continue to evaluate our options pertaining to a licensing arrangement for COTI-2."


'/>"/>

Contact: Michael Barr
mbarr@criticaloutcome.com
519-858-5157
Critical Outcome Technologies Inc
Source:Eurekalert

Page: 1 2

Related biology news :

1. ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER
2. Gamma globulin effective in treating eye infections caused by adenoviruses
3. UC health news: molecular pathway may predict chemotherapy effectiveness
4. Socioeconomic position associated with effectiveness of HIV drugs
5. New nanoparticle vaccine is more effective but less expensive
6. MIT model could improve some drugs effectiveness
7. Trial seeks genetic fingerprint for predicting drug effectiveness
8. New hope for horse lovers as effective control for killer ragwort is proposed
9. Quantitative PET imaging finds early determination of effectiveness of cancer treatment
10. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
11. Tamiflu effective for treatment and prevention of influenza in children 1 year and older
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/14/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) ... Market in Smart Mobile Devices " report to ... was a watershed year for fingerprint sensors in smartphones ... Apple gave fingerprint sensors a raison d,etre in the ... are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... East Asia is where the wolf was tamed and became the ... But now researchers at the Royal Institute of Technology (KTH) in ... "For the first time in world history it is possible to ... in time, and how many wolves were tamed," says Peter Savolainen, ...
... and other aquatic fauna in recent centuries are not restricted ... that species in rivers and lakes worldwide also experienced sharp ... is frequently overlooked by natural resource managers, according to an ... , Authors Paul Humphries and Kirk Winemiller argue that as ...
... Three out of ten women who undergo polar body ... of polar body analysis (PBA) is described by researchers in ... edition of Deutsches rtzeblatt International , in which they ... Int 2009; 106(33): 533-8). Polar bodies are by-products of ...
Cached Biology News:Shifting baselines confound river restoration 2New developments in reproductive medicine 2
(Date:6/2/2015)... 2015 Cirrascale Corporation ®, ... rackmount computing and storage infrastructure for conventional and ... its high density scale-out, two-in-one video delivery and ... . The high density, two-in-one system supports the ... with Intel® Iris™ Pro graphics P6300 and provides ...
(Date:6/2/2015)... , June 2, 2015   Y-Prime, Inc ... the BIO Exhibition 2015 in Philadelphia ... world,s largest biotechnology gathering, allows influential decision makers ... where they can evaluate emerging technologies such as ... expertise in the design, implementation and management of ...
(Date:6/2/2015)...   BioClinica ® , Inc., a specialty ... David Peters , an accomplished senior finance and ... Chief Financial Officer (CFO) and will be joining BioClinica ... than 25 years of financial and accounting experience with ... deep knowledge in all areas of finance, accounting and ...
(Date:6/2/2015)... , June 2, 2015   Sigma-Aldrich Corporation ... and Technology company, announced today it has entered ... to launch genetically engineered human neural differentiated cells ... research of neurological diseases. These new products, in ... and versatile tools for the study of central ...
Breaking Biology Technology:Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2BioClinica Names David Peters New Chief Financial Officer 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3
... Shows No Thrombosis, Low MACE Rates ... Thirty Patients, ABBOTT PARK, Ill., March 13 ... first clinical trial of a,fully bioabsorbable drug eluting stent ... thrombosis, no clinically driven target,lesion revascularizations (retreatment of a ...
... call scheduled for 5:00 pm ET today, ... NPSP ) today reported 2007 financial results,and ... strategy to,develop the company,s late-stage product candidates in ... unmet,medical need., In line with its new ...
... Trubion Pharmaceuticals,Inc. (Nasdaq: TRBN ) today announced financial results ... well as 2008 financial guidance., Fourth Quarter and Year ... 2007 was $5.7 million compared with,$6.4 million for the fourth ... was $20.1 million compared with $36.5 million for the year,ended ...
Cached Biology Technology:The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 4NPS Pharmaceuticals Reports 2007 Financial Results 2NPS Pharmaceuticals Reports 2007 Financial Results 3NPS Pharmaceuticals Reports 2007 Financial Results 4NPS Pharmaceuticals Reports 2007 Financial Results 5NPS Pharmaceuticals Reports 2007 Financial Results 6NPS Pharmaceuticals Reports 2007 Financial Results 7NPS Pharmaceuticals Reports 2007 Financial Results 8NPS Pharmaceuticals Reports 2007 Financial Results 9Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook 2Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook 3Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook 4Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook 5Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook 6
HSPBP1 Antibody...
golgi reassembly stacking protein 2, 55kDa...
...
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Biology Products: